UBS AM
IMCR icon

UBS AM’s Immunocore IMCR Stock Holding History

UBS AM’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Hold
185
– – ﹤0.01% 3374
2026
Q1 		$5.58K Buy
+185
New +$5.99K ﹤0.01% 3441
2025
Q3 		– Sell
-6,450
Closed -$202K – 2432
2025
Q2 		$202K Buy
6,450
+3,550
+122% +$110K ﹤0.01% 2562
2025
Q1 		$86K Buy
+2,900
New +$87K ﹤0.01% 2602
2024
Q4 		– Sell
-92,257
Closed -$2.87M – 2709
2024
Q3 		$2.87M Buy
92,257
+91,033
+7,437% +$3.31M ﹤0.01% 1845
2024
Q2 		$41.5K Sell
1,224
-92,893
-99% -$4.74M ﹤0.01% 2784
2024
Q1 		$6.12M Sell
94,117
-11,568
-11% -$794K ﹤0.01% 1170
2023
Q4 		$7.22M Sell
105,685
-1,577
-1% -$82K ﹤0.01% 1110
2023
Q3 		$5.57M Sell
107,262
-4,238
-4% -$251K ﹤0.01% 1166
2023
Q2 		$5.51M Hold
111,500
– – ﹤0.01% 1187
2023
Q1 		$5.51M Sell
111,500
-1,400
-1% -$78.7K ﹤0.01% 1187
2022
Q4 		$6.44M Buy
112,900
+34,438
+44% +$1.94M ﹤0.01% 1088
2022
Q3 		$3.68M Buy
+78,462
New +$3.74M ﹤0.01% 1308

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS AM's IMCR Position: Q2 2026 in Review

UBS AM held its Immunocore (IMCR) position steady in Q2 2026 at 185 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3374.

UBS AM first reported a position in IMCR in Q3 2022 and has held it in 13 quarters since. The position peaked at $7.22M in Q4 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • UBS AM held 185 shares of Immunocore worth $5.87K as of Q2 2026.
  • UBS AM left its Immunocore share count unchanged in Q2 2026.
  • Immunocore made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3374 holding.
  • UBS AM first reported a position in Immunocore in Q3 2022 and has held it in 13 quarters since.
  • UBS AM's Immunocore position peaked at $7.22M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.